Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N

MT Newswires Live07-22

Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights to jointly develop QX005N, and an optional right to market it in the field of healthcare in the greater China region, a Sunday filing with the Hong Kong Exchange said.

QX005N is a monoclonal antibody (mAb) blocking IL-4RÎ± and has received up to seven Investigational New Drug Application approvals from relevant authorities for indications like atopic dermatitis, prurigo nodularis, and chronic rhinosinusitis with nasal polyps.

Under the agreement, the parties will conduct the clinical and non-clinical studies and registration-related work of the subject product together and if Zhongmei agrees to market the product as well then it will be responsible for the marketing and promotion of the product in the greater China region.

Cellularforce, a subsidiary of the company will produce the clinical trial samples of the product.

The company's shares were up nearly 2% on Monday's close.

Price (HKD): $20.10, Change: $+0.34, Percent Change: +1.72%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453761390?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-22 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453761390","market":"sh","top_or_hot":-1,"title":"Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N","media":"MT Newswires Live","content":"<html><body><p> Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights to jointly develop QX005N, and an optional right to market it in the field of healthcare in the greater China region, a Sunday filing with the Hong Kong Exchange said.</p><p>QX005N is a monoclonal antibody (mAb) blocking IL-4RÎ± and has received up to seven Investigational New Drug Application approvals from relevant authorities for indications like atopic dermatitis, prurigo nodularis, and chronic rhinosinusitis with nasal polyps.</p><p>Under the agreement, the parties will conduct the clinical and non-clinical studies and registration-related work of the subject product together and if Zhongmei agrees to market the product as well then it will be responsible for the marketing and promotion of the product in the greater China region.</p><p>Cellularforce, a subsidiary of the company will produce the clinical trial samples of the product.</p><p>The company's shares were up nearly 2% on Monday's close.</p><p>Price (HKD): $20.10, Change: $+0.34, Percent Change: +1.72%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights to jointly develop QX005N, and an optional right to market it in the field of healthcare ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453761390","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453761390","pubTimestamp":1721649899,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights to jointly develop QX005N, and an optional right to market it in the field of healthcare i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","02509":"荃信生物-B","BK4139":"生物科技","BK4526":"热门中概股","BK4588":"碎股","HKD":"尚乘数科","BK4023":"应用软件","LENZ":"Therapeutics"},"translate_title":"Qyuns Therapeutics进入QX005N的开发和潜在商业化合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"LENZ":1,"02509":0.9},"content_text":"Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights to jointly develop QX005N, and an optional right to market it in the field of healthcare in the greater China region, a Sunday filing with the Hong Kong Exchange said.QX005N is a monoclonal antibody (mAb) blocking IL-4RÎ± and has received up to seven Investigational New Drug Application approvals from relevant authorities for indications like atopic dermatitis, prurigo nodularis, and chronic rhinosinusitis with nasal polyps.Under the agreement, the parties will conduct the clinical and non-clinical studies and registration-related work of the subject product together and if Zhongmei agrees to market the product as well then it will be responsible for the marketing and promotion of the product in the greater China region.Cellularforce, a subsidiary of the company will produce the clinical trial samples of the product.The company's shares were up nearly 2% on Monday's close.Price (HKD): $20.10, Change: $+0.34, Percent Change: +1.72%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453761390"}